Aravive, Inc.: directors' dealings · United States · SEC (Form 4)

About Aravive, Inc.

Aravive, Inc. is a U.S.-based biopharmaceutical company that was focused on oncology and, more broadly, the development of therapies intended to slow the progression of severe diseases. The company was incorporated in 2008 in Delaware and had its headquarters and principal operations in Houston, Texas, United States. Its shares traded on the Nasdaq market under the ticker ARAV. In January 2024, Aravive announced plans to delist from Nasdaq and to suspend its public reporting obligations in connection with an asset transfer for the benefit of creditors and a planned liquidation. For investors, that context is crucial: Aravive should be viewed as a restructuring/special-situation name rather than a conventional operating growth stock. From a business-model standpoint, Aravive was a clinical-stage company with no established commercial product base. Its value proposition was built around research and development, with the company seeking to advance a lead candidate, AVB-500. AVB-500 is an ultra-high-affinity decoy protein designed to intercept the GAS6-AXL signaling pathway. That pathway has been studied in cancer biology because of its potential links to tumor growth, cell survival, metastasis, and treatment resistance. In practical terms, Aravive’s core activity was drug discovery and clinical validation, not manufacturing or the sale of approved therapies. The company’s market position was therefore that of a small, highly specialized biotechnology developer operating in one of the most competitive areas of healthcare innovation. Aravive competed indirectly with much larger oncology franchises at diversified pharmaceutical companies, as well as with numerous venture-backed biotech peers pursuing targeted cancer mechanisms. Its differentiation came from the scientific rationale of the GAS6-AXL target and the specificity of its decoy-protein approach. However, the downside was equally clear: extreme dependence on capital markets, high research spending, binary clinical risk, and limited diversification. Those are typical characteristics of early-stage biotech, but they became especially important as Aravive’s financial and listing situation deteriorated. Historically, the company’s profile was one of a single-lead-asset biotech, meaning investor attention was concentrated on pipeline progress, trial readouts, financing events, and strategic alternatives. Its geographic footprint was centered in the United States, with Houston as the main corporate base. The most important recent development was not a product launch or a regulatory approval, but the company’s move toward delisting and liquidation in 2024. That makes Aravive a name primarily relevant for event-driven investors and analysts following distressed healthcare situations, rather than for long-term fundamental growth investors.